Acquired Company

Neoleukin Therapeutics acquired Neurogene on 12/19/2023, with Neurogene becoming a wholly owned subsidiary of Neoleukin upon completion of the merger.

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York. Show more

535 W 24th Street, New York, NY, 10011, United States

https://www.neurogene.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

286.4M

52 Wk Range

$6.88 - $37.27

Previous Close

$18.49

Open

$18.49

Volume

55,486

Day Range

$18.49 - $19.26

Enterprise Value

37.76M

Cash

265.4M

Avg Qtr Burn

-19.51M

Insider Ownership

8.54%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NGN-401 Details Rett syndrome	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NGN-101 Details Rare genetic disease, Batten Disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.